Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Lucid Diagnostics Inc. is a U.S.-based commercial-stage medical diagnostics company focused on the early detection of esophageal precancer and cancer. The company operates within the molecular diagnostics and gastroenterology segments of the healthcare industry, with a specific emphasis on improving screening for Barrett’s esophagus and esophageal adenocarcinoma, diseases that are historically underdiagnosed using conventional endoscopic methods.
The company’s primary revenue drivers are its proprietary diagnostic test EsoGuard®, a DNA-based molecular assay, and its complementary noninvasive cell collection device EsoCheck®. Lucid Diagnostics targets primary care providers, gastroenterologists, and integrated healthcare systems, positioning its technology as a less invasive, scalable alternative to traditional endoscopy. The company was founded in 2018 and became publicly listed in 2021 through a spinout from PAVmed Inc., which remains a significant shareholder and strategic partner.
Business Operations
Lucid Diagnostics operates as a single-reportable segment focused on the commercialization of its esophageal diagnostic platform. Revenue is generated through laboratory-developed testing services performed at the company’s CLIA-certified laboratory, where EsoGuard® samples collected using EsoCheck® are processed and analyzed. The company controls its core intellectual property related to biomarker detection, sample collection, and testing protocols.
Operations are primarily domestic, with commercialization efforts concentrated in the United States. Lucid maintains strategic relationships with physician practices, health systems, and payors to support adoption and reimbursement. The company also benefits from ongoing operational and historical ties to PAVmed Inc., including shared intellectual property origins and prior intercompany services, though Lucid operates as an independent public entity.
Strategic Position & Investments
Lucid Diagnostics’ strategy centers on expanding physician adoption, securing broader insurance reimbursement, and increasing awareness of noninvasive esophageal cancer screening. Growth initiatives include scaling its commercial sales organization, expanding laboratory capacity, and generating additional clinical and health-economic data to support guideline inclusion and payor coverage decisions.
The company has not pursued large-scale acquisitions and instead focuses investment on internal development and commercialization of its existing platform. Its core technology is positioned at the intersection of molecular diagnostics and preventive oncology, with ongoing evaluation of additional biomarker applications. Lucid Diagnostics remains closely aligned with PAVmed Inc. as a strategic shareholder, though no material portfolio of external subsidiaries has been disclosed.
Geographic Footprint
Lucid Diagnostics is headquartered in the United States, with corporate offices in New York and laboratory operations in Tennessee. Its commercial activities are focused exclusively on the U.S. healthcare market, reflecting the regulatory, reimbursement, and clinical pathways relevant to its diagnostic offerings.
While the company does not currently report international operations or revenue, its technologies are theoretically adaptable to other developed healthcare markets. Any future geographic expansion would likely depend on regulatory approvals, reimbursement frameworks, and strategic partnerships outside North America, none of which have been formally announced.
Leadership & Governance
Lucid Diagnostics was founded by leadership affiliated with PAVmed Inc. and continues to reflect a governance structure oriented toward clinical innovation and capital-efficient commercialization. The leadership team emphasizes early cancer detection, evidence-based medicine, and disruption of invasive diagnostic paradigms through scalable technologies.
Key executives include:
- Lishan Aklog, MD – Chairman and Chief Executive Officer
- Stephen W. Wiggins – Chief Financial Officer
Public disclosures identify additional senior management roles; however, detailed confirmation of other executive appointments is limited based on available public sources. Data inconclusive based on available public sources for additional executive officers beyond those listed above.